The utility of gene sequencing in identifying an underlying genetic disorder in prenatally suspected lower urinary tract obstruction
Bobby K. Brar, Karin Blakemore, Christine Hertenstein, Jena L. Miller, Kristen A. Miller, Hanan Shamseldin, Sateesh Maddirevula, Thomas Hays, Billie Lianoglou, Stephanie Dukhovny, Linda A. Baker, Teresa N. Sparks, Ronald Wapner, Fowzan S. Alkuraya, Mary E. Norton, Angie C. Jelin,- Genetics (clinical)
- Obstetrics and Gynecology
Abstract
Objective
Fetal megacystis generally presents as suspected lower urinary tract obstruction (LUTO), which is associated with severe perinatal morbidity. Genetic etiologies underlying LUTO or a LUTO—like initial presentation are poorly understood. Our objectives are to describe single gene etiologies in fetuses initially ascertained to have suspected LUTO and to elucidate genotype‐phenotype correlations.
Methods
A retrospective case series of suspected fetal LUTO positive for a molecular diagnosis was collected from five centers in the Fetal Sequencing Consortium. Demographics, sonograms, genetic testing including variant classification, and delivery outcomes were abstracted.
Results
Seven cases of initially prenatally suspected LUTO‐positive for a molecular diagnosis were identified. In no case was the final diagnosis established as urethral obstruction that is, LUTO. All variants were classified as likely pathogenic or pathogenic. Smooth muscle deficiencies involving the bladder wall and interfering with bladder emptying were identified in five cases: MYOCD (2), ACTG2 (2), and MYH11 (1). Other genitourinary and/or non‐genitourinary malformations were seen in two cases involving KMT2D (1) and BBS10 (1).
Conclusion
Our series illustrates the value of molecular diagnostics in the workup of fetuses who present with prenatally suspected LUTO but who may have a non‐LUTO explanation for their prenatal ultrasound findings.